Literature DB >> 22855142

Chemotherapy at the end of life: up until when?

Jaime Sanz Ortiz1.   

Abstract

AIM: The aim of this study is to analyze the use of CT in terminal stage cancer and the percentage of patients who received UCPD in 2009 and 2010 on the Medical Oncology and Palliative Home Care integrated service (UCPD) ward of the Marqués de Valdecilla University Hospital.
METHOD: Retrospective analysis of death rate registered on the Medical Oncology ward for 2009 and 2010 and the recorded date of the last CT given. The data are analyzed using the SPSS version 15.0 statistic package. Data were obtained from the Database Minimum Set for oncology admissions.
RESULTS: The death rate on the Medical Oncology ward is 22-24%. Total number of cases studied is 303. 47% of patients are aged 60 or younger. 81.8% (248) received active cancer treatment; of these, 138 (55.6%) in the last month, and 84 (33.8%) in the last 2 weeks. Only 66 patients out of those who died on the ward (21%) were previously sent to the UCPD.
CONCLUSIONS: Even when it is known that the majority of cancer patients become resistant to CT at the end of their lives, it is often given to patients of all ages. The request for palliative care is rare and often late.

Entities:  

Mesh:

Year:  2012        PMID: 22855142     DOI: 10.1007/s12094-012-0847-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  34 in total

1.  Bridging the divide: integrating cancer-directed therapy and palliative care.

Authors:  Jennifer L Malin
Journal:  J Clin Oncol       Date:  2004-07-26       Impact factor: 44.544

2.  The autopsy as a performance measure and teaching tool.

Authors:  Richard E Horowitz; Wesley Y Naritoku
Journal:  Hum Pathol       Date:  2007-03-21       Impact factor: 3.466

3.  [Uneasiness or uncomfortably: is it a symptom ovenproof in the end of life?].

Authors:  Jaime Sanz Ortiz; Alfonso Martín Carnicero
Journal:  Med Clin (Barc)       Date:  2009-04-22       Impact factor: 1.725

4.  Bending the cost curve in cancer care.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

5.  Availability and integration of palliative care at US cancer centers.

Authors:  David Hui; Ahmed Elsayem; Maxine De la Cruz; Ann Berger; Donna S Zhukovsky; Shana Palla; Avery Evans; Nada Fadul; J Lynn Palmer; Eduardo Bruera
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

6.  Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center.

Authors:  Shalini Dalal; Shana Palla; David Hui; Linh Nguyen; Ray Chacko; Zhijun Li; Nada Fadul; Cheryl Scott; Veatra Thornton; Brenda Coldman; Yazan Amin; Eduardo Bruera
Journal:  Oncologist       Date:  2011-01-06

7.  Factors that affect the duration of the interval between the completion of palliative chemotherapy and death.

Authors:  Kenji Hashimoto; Kan Yonemori; Noriyuki Katsumata; Marika Hotchi; Tsutomu Kouno; Chikako Shimizu; Kenji Tamura; Masashi Ando; Masahiro Takeuchi; Yasuhiro Fujiwara
Journal:  Oncologist       Date:  2009-07-11

8.  Chemotherapy use and associated factors among cancer patients near the end of life.

Authors:  Young Ho Yun; Miyoung Kwak; Sang Min Park; Samyong Kim; Jong Soo Choi; Ho-Yeong Lim; Chang Geol Lee; Youn Seon Choi; Young Seon Hong; Si-Young Kim; Dae Seog Heo
Journal:  Oncology       Date:  2007-12-20       Impact factor: 2.935

9.  Have we looked beyond the physical and psychosocial?

Authors:  D Doyle
Journal:  J Pain Symptom Manage       Date:  1992-07       Impact factor: 3.612

10.  Decrease in the frequency of autopsies in Denmark after the introduction of a new autopsy act.

Authors:  C N Petri
Journal:  Qual Assur Health Care       Date:  1993-12
View more
  8 in total

1.  Should be NICE have a Spanish NICE?

Authors:  J Feliu; E Espinosa
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

2.  Association between the duration of palliative care service and survival in terminal cancer patients.

Authors:  Yong Joo Lee; Jung-Hwa Yang; Jung-Wook Lee; Johi Yoon; Jung-Ran Nah; Whan-Seok Choi; Chul-Min Kim
Journal:  Support Care Cancer       Date:  2014-10-04       Impact factor: 3.603

3.  Treatment of cancer patients in their last month of life: aimless chemotherapy.

Authors:  Tarek Assi; Elie El Rassy; Samer Tabchi; Toni Ibrahim; Tania Moussa; Ralph Chebib; Fadi El Karak; Fadi Farhat; Georges Chahine; Fadi Nasr; Marwan Ghosn; Joseph Kattan
Journal:  Support Care Cancer       Date:  2015-09-21       Impact factor: 3.603

4.  Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital.

Authors:  Syed Mustafa Karim; Jamal Zekri; Ehab Abdelghany; Reyad Dada; Husna Munsoor; Imran Ahmad
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

5.  Use of chemotherapy at the end of life in Turkey.

Authors:  Sema Sezgin Goksu; Seyda Gunduz; Dilek Unal; Mukremin Uysal; Deniz Arslan; Ali M Tatlı; Hakan Bozcuk; Mustafa Ozdogan; Hasan S Coskun
Journal:  BMC Palliat Care       Date:  2014-11-19       Impact factor: 3.234

6.  Palliative care and end-of-life measure outcomes: Experience of a tertiary care institute from South India.

Authors:  Praveen Adusumilli; Lingaraj Nayak; Vidya Viswanath; Leela Digumarti; Raghunadha Rao Digumarti
Journal:  South Asian J Cancer       Date:  2018 Jul-Sep

7.  Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution.

Authors:  Tae-Kyu Jang; Dae-Yeon Kim; Shin-Wha Lee; Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  BMC Palliat Care       Date:  2018-08-07       Impact factor: 3.234

Review 8.  Quality Assessment in Supportive Care in Head and Neck Cancer.

Authors:  Pierluigi Bonomo; Alberto Paderno; Davide Mattavelli; Sadamoto Zenda; Stefano Cavalieri; Paolo Bossi
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.